The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Does The Forecasted Market Size Of The Biomarkers Market Compare Between 2026 And 2030?
The biomarkers market has experienced rapid growth in recent years. It is forecast to expand from $77.42 billion in 2025 to $88.42 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.2%. This historical growth can be attributed to progress in molecular biology, increasing pharmaceutical research and development expenditure, a rise in cancer prevalence, more widespread use in clinical trials, and the demand for targeted therapies.
The biomarkers market is projected to experience substantial expansion in the coming years. This market is expected to reach $150.52 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.2%. This anticipated growth during the forecast period is driven by several factors, including the proliferation of personalized treatment methods, the growing acceptance of liquid biopsy biomarkers, augmented regulatory backing for drugs relying on biomarkers, advances in neurological disease research, and enhanced partnerships between pharmaceutical and diagnostic companies. Key trends expected over this period involve the increasing application of biomarkers in precision medicine, their deeper integration into drug discovery and development processes, wider usage in managing oncology and chronic diseases, the broadening scope of companion diagnostics, and a sharpened emphasis on identifying diseases at early stages.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6485&type=smp
Which Strategic Drivers Are Supporting The Biomarkers Market Development?
The anticipated rise in heart conditions is projected to boost the expansion of the biomarkers market over the forecast period. Over recent years, the application of biomarkers in patients suffering from heart disease has grown significantly. At present, natriuretic peptides represent the most frequently utilized biomarker, assisting in the diagnosis of individuals with heart failure. For diagnosing heart failure, biomarkers like circulating biomarkers with high sensitivity C-reactive protein are employed. In the United States, heart disease stands as a primary cause of mortality across a majority of racial and ethnic demographics. This surge in heart diseases is expected to fuel the demand for biomarkers. An illustrative example is provided by the British Heart Foundation, a UK-based charity, which reported in September 2025 that over 7.6 million people (comprising more than 4 million men and over 3.6 million women) are living with cardiovascular disease throughout the UK. Furthermore, projections suggest that this figure could increase by approximately 1 million by 2030 and by roughly 2 million by 2040, primarily due to an aging population and enhanced survival rates. Consequently, the expanding prevalence of heart diseases is accelerating the growth of the biomarkers market.
How Is The Biomarkers Market Examined Through Segment Analysis?
The biomarkers market covered in this report is segmented –
1) By Technology: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers
2) By Disease: Neurological Diseases, Cancer, Immunological Diseases, Cardiovascular Diseases, Other Diseases
3) By Type: Biomarker Of Exposure, Biomarker Of Diseases
4) By Audiences: Pharmaceutical Companies, Government And Private Research Institutes, Academic Institutes, Medical Device Manufacturing Companies
Subsegments:
1) By Safety Biomarkers: Toxicity Biomarkers, Pharmacokinetic Biomarkers, Adverse Effect Biomarkers
2) By Efficacy Biomarkers: Pharmacodynamic Biomarkers, Disease Progression Biomarkers, Treatment Response Biomarkers
3) By Validation Biomarkers: Analytical Validation Biomarkers, Clinical Validation Biomarkers, Qualification Biomarkers
Which Trends Are Influencing The Expansion Of The Biomarkers Market?
Companies operating in the biomarker market are creating innovative products, such as biomarker tests, to reach broader customer bases, increase sales, and grow revenue. Biomarker tests, also termed biomarker assays, represent laboratory techniques or diagnostic evaluations that identify specific biological markers, which can encompass molecules, genes, proteins, or other substances, offering information about various physiological or pathological activities within the body. For example, in July 2023, Quest Diagnostics, a US-based medical laboratories company, introduced a novel prostate cancer biomarker test. This new tissue-based test service seeks to address the urgent clinical need for tests that can aid in distinguishing potentially aggressive cases of prostate cancer in males. Quest developed and validated this laboratory test through an intellectual property license agreement with Envision, allowing the application of Envision’s exclusive biomarker and immunohistochemistry technology, which incorporates Envision’s distinct staining methods and innovative biomarkers referred to as EV1, EV2, and EV3.
Which Companies Are Engaged In The Biomarkers Market Environment?
Major companies operating in the biomarkers market are Enzo Biochem Inc, Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., QIAGEN N. V., Adaptive Biotechnologies Corp., Agilent Technologies Inc., Biocrates Life Sciences AG, BioFire Diagnostics LLC, BioReference Laboratories Inc., Bio-Techne Corporation, Cepheid Inc., Eurofins Scientific SE, Exact Sciences Corporation, Foundation Medicine Inc., Genomic Health Inc., GenScript Biotech Corporation, Guardant Health Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation, Metabolon Inc., Myriad Genetics Inc., Natera Inc., Pacific Biosciences of California Inc., Quest Diagnostics Incorporated, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Veracyte Inc.
Access The Complete Biomarkers Market Report:
https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report
Which Regional Market Leads The Biomarkers Market?
North America was the largest region in the biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Biomarkers Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=6485&type=smp
Browse Through More Reports Similar to the Global Biomarkers Market 2026, By The Business Research Company
Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report
Clinical Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report
Cancer Biomarker Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model